Evaluation of the effect of Eplerenone in Central serous chorioretinopathy )CSCR

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220122053792N1

Enrollment

Registered

2022-03-06

Start date

2022-01-15

Completion date

Unknown

Last updated

2022-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic central serous chorioretinopathy. Central serous chorioretinopathy

Interventions

Intervention 1: Intervention group:For patients in the intervention group, Eplerenone will be administered at a dose of 25 mg for one week and then at a dose of 50 mg for three weeks. Intervention 2:

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with chronic central serous chorioretinopathy

Exclusion criteria

Exclusion criteria: Elevated potassium levels in preoperative blood testsor contraindications in comprehensive medical examination renal impairment severe hepatic impairment known allergies to any of the components of the drug

Design outcomes

Primary

Measure	Time frame
The patient's best corrected vision. Timepoint: Before and one month after the start of the intervention. Method of measurement: snellen chart.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Qader Motarjemizadeh

Oroumia University of Medical Sciences

Motarjemizadeh.q@umsu.ac.ir0984433469931

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026